Twirla®

(levonorgestrel and ethinyl estradiol) transdermal system 120 mcg/day levonorgestrel and 30 mcg/day ethinyl estradiol

Twirla is a once weekly combined hormonal contraceptive patch.

Afaxys is an authorized promotional partner for Twirla®.

NDC#

71671-100-03

View Full Prescribing Information, Including Boxed Warning
Twirla Twirla Twirla Twirla
Twirla
Twirla
Twirla
Twirla

Product Details

  • Twirla is the first and only combined hormonal once-weekly birth control patch delivering a low dose of estrogen.1-5
  • Twirla is for use in women of reproductive potential with a BMI <30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Consider Twirla’s reduced effectiveness in women with a BMI ≥25 to <30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI > 30 kg/m2.
  • Delivers 30 mcg of estrogen daily, the lowest exposure of estrogen in a transdermal contraceptive option.2-4
  • Proprietary patch technology, designed with a woven, flexible fabric and proven to stay in place.1 In a clinical trial, 95% of Twirla patches adhered, while 5% of patches fully detached.
  • Each box contains 3 Twirla transdermal systems

Product Features:

  • A noninvasive method without the need for same-time-every-day dosing1
  • Once-weekly application: patients wear 1 patch every week for 3 weeks and no patch during week 4. Patient should check daily to ensure edges haven’t lifted.
  • Self-applied to one of the following locations on the skin: buttock, abdomen, or upper torso (excluding the breast).1,2 The most common side effects reported by women using Twirla in a clinical study were skin reactions at the patch site, nausea, headache, dysmenorrhea, and weight gain.
  • Estrogen delivery over 7 days without the daily serum highs and lows of oral delivery2
  • Efficacy and safety were established in a purposefully inclusive trial that featured a diverse study population, closely representative of the demographics of women across the US1
  • In the SECURE Trial, Twirla was found to be a safe with proven tolerability as a weekly option in women with a BMI <30 kg/m2 for whom a combined hormonal contraceptive is appropriate1,2

Visit Twirla.com/HCP for more information, resources, and tools.

Take a closer look at Twirla and its novel Skinfusion technology: Watch the Twirla Patch Design video

Help your patients learn how to apply Twirla: Watch the Twirla Patch Application video

View Full Prescribing Information, Including Boxed Warning

Distributor & Ordering Info

Twirla®

NDC#: 71671-100-03

Package Size: Box containing 3 transdermal systems

Distributor Phone URL Order Number
ANDA 1-800-331-2632 (Ext. 74591) andanet.com 331094
ASD Healthcare 1-800-746-6273 asdhealthcare.com 710027
R & S Northeast 1-800-262-7770 rsnortheast.com 01000300

Order Twirla® (levonorgestrel and ethinyl estradiol) transdermal system

Order Now

Contact Your
Afaxys Pharma
Account Manager

Contact Now

View All
Afaxys Pharma
Products

View Now
Need help? Contact an Afaxys Account Manager